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Purpose: Given the rapid pace of discovery in rare disease
genomics, it is likely that improvements in diagnostic yield can be
made by systematically reanalyzing previously generated genomic
sequence data in light of new knowledge.
Methods: We tested this hypothesis in the United Kingdom–wide
Deciphering Developmental Disorders study, where in 2014 we
reported a diagnostic yield of 27% through whole-exome sequen-
cing of 1,133 children with severe developmental disorders and
their parents. We reanalyzed existing data using improved variant
calling methodologies, novel variant detection algorithms, updated
variant annotation, evidence-based filtering strategies, and newly
discovered disease-associated genes.
Results: We are now able to diagnose an additional 182
individuals, taking our overall diagnostic yield to 454/1,133
(40%), and another 43 (4%) have a finding of uncertain clinical
significance. The majority of these new diagnoses are due to novel
developmental disorder–associated genes discovered since our
original publication.
Conclusion: This study highlights the importance of coupling large-
scale research with clinical practice, and of discussing the possibility of
iterative reanalysis and recontact with patients and health professionals
at an early stage. We estimate that implementing parent–offspring
whole-exome sequencing as a first-line diagnostic test for develop-
mental disorders would diagnose > 50% of patients.
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INTRODUCTION
The relative affordability and accessibility of next-generation
sequencing have facilitated the development of family-based
genomic analysis, resulting in an explosion of gene discovery
and diagnosis for rare diseases.1–3 Diagnosis rates—here
defined as the confident causal association of a genotype with
the presenting phenotype—vary from 20 to 60% depending
on numerous factors, including specificity of the clinical
presentation, genetic heterogeneity of the disease, patient
recruitment criteria, sequencing technology and analytical
workflow, evidence of de novo occurrence of causal variants,
and date of publication.4–6 The latter in part reflects the
accelerated rate of analytical tool development and gene
discovery catalyzed by next-generation sequencing.7 Given
the pace of change throughout the field, some diagnostic
variants must be presumed to be unrecognized during the
initial analysis of genomic data, and without intervention,
may remain undiscovered. Systematic, retrospective reanalysis
of genomic data is therefore likely to improve diagnostic
yield.8 However, the logistical challenges of performing
regular reanalyses, coupled with reinterpretation of the results
and recontacting of clinicians and patients, are substantial.9
To date, although several small-scale examples of this
approach exist,10,11 no large-scale diagnostic reanalyses have
been published, so the potential benefits of this methodology
when applied systematically across an entire cohort are
currently unquantified.
Due to the extremely large number of variants in every
genome, evidence-based filters are applied to prioritize
potentially relevant variants for individual clinical cases. A
balance must be struck between sensitivity and specificity to
find potential diagnoses without being overwhelmed by false
positive results. As a result, there are numerous reasons why
diagnostic variants might not be recognized during the
analysis of genomic data, e.g., technical failure to detect a
variant in the data, incorrect annotation, limited knowledge of
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the causative loci, or inappropriate exclusion of a variant
(Table 1).10 It is therefore beholden upon researchers
involved in large-scale translational research studies to
consider re-evaluating their protocols and reanalyzing their
data, and also on clinical services to consider how
reinterpreting data, reclassifying variants, and recontacting
patients can best be managed.
The Deciphering Developmental Disorders (DDD) study
(http://www.ddduk.org) provides an ideal cohort for devel-
oping and testing how such an iterative model of reanalysis
and re-reporting might work at scale. The DDD study is a
United Kingdom–wide collaboration between the National
Health Service (NHS) Regional Genetics Services across the
United Kingdom and Ireland and the Wellcome Trust Sanger
Institute, which aims to both delineate the genetic architecture
of developmental disorders and improve the diagnosis of
these disorders in clinical practice using high-throughput
genetic technologies. From April 2011 to 2015, the DDD
study recruited ~ 13,500 families with severe, undiagnosed
developmental disorders, including ~ 10,000 complete par-
ent–offspring trios, all of whom have had all known coding
genes sequenced (exome sequencing). In addition to con-
ducting large-scale, statistical research into novel genetic
causes of developmental disorders,12,13 the DDD study also
returns plausible diagnostic results to individual families via
~ 200 referring consultant clinical geneticists, who are
responsible for their ongoing care.14 The identification and
communication of plausible diagnostic variants from the
DDD study was initially designed to be conservative, to
maximize positive predictive value while avoiding incorrect
diagnosis, with the expectation that the methodology would
be largely automated and improved iteratively throughout the
study in light of new data and knowledge. An important
question is therefore how much of an improvement in
diagnostic yield is achievable in a clinically ascertained cohort
over time. Here, we reanalyze the data from the first 1,133
family trios recruited into the study, describe improvements
in the analysis and interpretation workflow, and compare the
findings with our initial analysis of this cohort from 3 years
earlier.14
MATERIALS AND METHODS
Patient recruitment and assays
Children with severe undiagnosed neurodevelopmental dis-
orders, and/or congenital anomalies, abnormal growth
parameters, dysmorphic features, and unusual behavioral
phenotypes, were recruited with their parents from 24
regional genetics services across the United Kingdom and
Ireland.12,14 Specific clinical data (growth, development,
family and pregnancy history, previous investigations, clinical
photographs) and Human Phenotype Ontology terms15 were
recorded by the regional clinical teams for the child and
parents via a secure online portal within the DECIPHER
database.16
Saliva and/or blood-extracted DNA samples were analyzed
at the Wellcome Trust Sanger Institute using whole-exome
Table 1 Potential analytical sources of missed diagnoses and corresponding improvements made to the DDD workflow
since 2014
Step Purpose Potential sources of missed diagnoses Changes to DDD workflow
Variant detection Sequence data is mapped to the
human genome reference, and
variation called relative to that
reference
Low-depth sequence data
Incorrect reference sequence
Incorrect mapping
Variant detection/genotyping failed
Variant class not considered (e.g., triplet
repeats)
Updated versions of BWA, SAMtools,
GATK, and DeNovoGear
Multisample variant calling
Additional variant detection algorithms
Variant
annotation and
filtering
Stringent filters are applied to
exclude low-quality, common, and
noncoding variants that are
unlikely to be clinically relevant
Low-quality variant discarded
Incorrect annotation of allele frequency
Incorrect annotation of consequence
Variant filtering thresholds too stringent
Updated version of VEP
Updated MAF data
Updated filtering thresholds (lower MAF,
exclusion of benign inherited missense
variants)
Gene
prioritization
Evidence-based, disease-specific
“virtual” gene panels are applied
to limit variants to those with a
relevant genotype (heterozygous/
homozygous) and inheritance
(dominant/recessive) in proven
disease-causing genes
Incorrect disease mechanism
Incorrect inheritance or family history
Incomplete penetrance
Phenotype not recorded
Known gene missing from panel
Causal gene not yet discovered
Updated DDG2P (November 2013 freeze
used previously; June 2016 freeze used
here, including 286 additional genes)
Plausibly pathogenic variants shared via
DECIPHER Research Track
Reviewed parental phenotypes
Clinical
assessment
Clinical assessment of the
pathogenicity and contribution of
specific variants to disease in a
specific individual/family
Patient phenotype differs from previously
published cases
Phenotype not yet developed
Evidence for pathogenicity is unclear
Candidate variants re-reviewed by core
DDD clinical team and/or referring
clinician
Some patients clinically assessed again
BWA, Burrows–Wheeler Aligner; DDD, Deciphering Developmental Disorders study; DDG2P, Developmental Disorder Gene-to-Phenotype database; GATK, Genome Ana-
lysis Toolkit; MAF, minor allele frequency; VEP, Variant Effect Predictor.
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sequencing of the family trio (Agilent SureSelect 55 MB
Exome Plus with Illumina HiSeq) and exon-resolution
microarray analysis of the proband (Agilent 2 × 1M array
CGH (Santa Clara, CA)).12 A selection of candidate variants
with low-quality metrics were subsequently validated using
targeted Sanger sequencing.
Variant detection and annotation
Mapping of short-read sequences was carried out using the
Burrows–Wheeler Aligner (version 0.59)17 algorithm with
the GRCh37 1000 Genomes Project phase 2 reference. The
Genome Analysis Toolkit (GATK; version 3.1.1)18 and
SAMtools (version 0.1.19)19 was used for sample-level BAM
improvement and multisample variant calling across all
samples. Ensembl Variant Effect Predictor20 based on
Ensembl gene build 76 was used to annotate variants. The
population prevalence (minor allele frequency) of each variant
was annotated using the Exome Aggregation Consortium
(ExAC),21 1000 Genomes Project,22 and internal data from all
unaffected (developmentally normal) DDD parents in the
cohort.
Numerous bespoke algorithms were also developed to
detect specific types of additional variation: DeNovoGear 23
was used to predict likely de novo single-nucleotide variants
(SNVs) and small insertions/deletions (indels) in the child,
augmented with candidate de novo indels called by GATK
and present in the child but not their parents; CNsolidate,
CoNVex, and CIFER were used respectively to detect copy-
number variants (CNVs) in the array CGH and exome data,
and to predict their inheritance (unpublished data); UPDio24
was used to detect uniparental disomy (UPD); triPOD25 was
used to detect structural mosaicism; a chromosome read-
depth counter was used to detect chromosomal aneuploidy
(unpublished data); and Indelible was used to detect soft-
clipped reads caused by midsized indels (unpublished data).
All annotated SNVs, indels, and CNVs for an individual were
combined into a single Variant Call Format file.
Variant filtering
An automated variant filtering pipeline was used to narrow
down the number of candidate diagnostic SNVs, indels, and
CNVs (Figure 1),14 using the following rules for family trios:
1. Allele frequency. Variants must be below a series of minor
allele frequency (MAF) cut-offs, using the maximum
MAF of the internal and external data combined: MAF
o0.0005 (0.05%) and ExAC heterozygous allele counto5
in dominant genes; MAF o0.0005 (0.05%) and ExAC
hemizygote allele count= 0 in hemizygous genes; MAF
o0.005 (0.5%) in recessive genes.
2. Predicted consequence. Variants must be predicted to
have a functional or loss-of-function consequence within
a coding gene, based on the transcript with the most severe
predicted consequence (longest or canonical selected
where there are multiple with the same consequence),
including transcript ablation, transcript amplification,
splice donor, splice acceptor, stop gained, frameshift, stop
lost, start lost, in-frame insertion, in-frame deletion, and
missense variants.
3. Gene and genotype. To target the analysis toward making
a primary diagnosis, variants must overlap a Confirmed
or Probable gene in our curated Developmental Disorder
Gene-to-Phenotype (DDG2P) database (http://www.ebi.
ac.uk/gene2phenotype),14 and the genotypes must match
the allelic requirement of the gene. A version of DDG2P
from June 2016 was used in this analysis. For SNVs/
indels, this includes single heterozygotes in dominant
genes, homozygotes and compound heterozygotes in
recessive genes, and X-chromosome hemizygotes in boys
in hemizygous genes. For CNVs, this includes deletions
and disruptive intragenic duplications in DDG2P genes
with a loss-of-function or dominant negative mechanism,
whole-gene/exon duplications in genes with an increased
gene dosage mechanism, and any large (>1MB) genic
deletions/duplications. SNV/CNV compound heterozy-
gotes were also evaluated in biallelic genes.
4. Inheritance. Variants in the proband must be inherited
in a manner that is both consistent with the family
history of disease (assuming full penetrance) and the
inheritance pattern of the gene (dominant/recessive/X-
linked), including de novo mutations in dominant and
X-linked genes (Sanger validation required if posterior
probability from DeNovoGear o0.1), inherited homo-
zygous and compound heterozygous variants in recessive
genes, inherited heterozygotes in dominant genes inher-
ited from a developmentally affected parent, maternally
inherited X-chromosome variants in boys (which are
Allele frequency & consequence
Gene and genotype (DDG2P)New genediscovery
Inheritance and family history
Clinical phenotype assessment
0–2 likely
diagnostic
1–4 with relevent
inheritance
10–20 in relevant
disease genes
400 rare & functional
~20,000 variants per exome
(or 4–5 million variants per genome)
Figure 1 Outline of DDD variant filtering and reporting workflow.
Details of thresholds are outlined in the Methods section. The entire
workflow is automated until the final stage, which requires detailed
clinical review of any candidate variants in light of the child’s specific
developmental phenotype. DDG2P, Developmental Disorder Gene-to-
Phenotype database.
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heterozygous in the mother and hemizygous in her son).
Inherited missense variants predicted to be benign by
PolyPhen226 were excluded.
Candidate variants identified through additional variant
detection algorithms (including UPD, aneuploidy, structural
mosaics, de novo nonessential splice sites, soft-clipped read
indels, and mosaic variants inherited from unaffected parents)
were analyzed and evaluated outside of this workflow.
Code availability
An updated version of the variant filtering code used by the
DDD study is available online at https://github.com/jeremym
crae/clinical-filter.
Variant sharing and genetic diagnosis
Candidate diagnostic variants passing the variant filtering
pipeline described above were evaluated by the DDD study’s
internal clinical review team (including two consultant clinical
geneticists) and communicated to the regional genetics
services via deposition in the DECIPHER database.16 Both
the DDD clinical team and the family’s local referring NHS
consultant clinical geneticist assessed the diagnostic contribu-
tion of the variant(s) to the child’s presenting condition in
each individual patient, based on the strength of the genetic
evidence (assessment of the variant and inheritance) together
with the phenotypic fit with previously reported cases. (UK
NHS Consultant clinical geneticists have undertaken a
minimum of 8 years training post clinical qualification
including a minimum of 4 years specialist training in clinical
genetics and rare disease diagnosis.) Likely diagnostic variant
(s) were subsequently confirmed in an accredited diagnostic
laboratory. Systematic functional studies were not performed,
though all reported variants are in published developmental
disorder genes with sufficient evidence to merit inclusion in
our curated gene-to-phenotype database (https://www.ebi.ac.
uk/gene2phenotype/).14 Variant interpretation was informed
by guidelines from both the American College of Medical
Genetics and Genomics27 and the UK Association for Clinical
Genetic Science, but with the overall assessment of patho-
genicity focused on an integrated clinical genetic diagnosis
including a composite of patient assessment, variant evalua-
tion, inheritance, and clinical fit. Clinical teams were asked to
record the results of these evaluations in the patient’s variant
DECIPHER record, and anonymized variants were made
publicly accessible after a short holding period.
In addition, plausibly pathogenic variants in genes not yet
associated with developmental disorders, detected in children
who remain undiagnosed after variant filtering, were
anonymized and shared via a research track in DECIPHER,
unlinked to the patient record, to facilitate variant
matchmaking.28,29 These included functional de novo variants
and rare loss-of-function homozygous, compound hetero-
zygous, and hemizygous variants in genes that are neither
DDG2P nor OMIM-morbid genes. Full genomic data sets
were deposited in the European Genome–Phenome Archive30
in accordance with the Regional Ethics Committee approval
for the study.
RESULTS
Using the variant detection and filtering workflow described,
we have achieved a full or partial diagnosis for 454 probands
in the first 1,133 family trios in the DDD study, correspond-
ing to a 40% diagnostic yield. Of these, 78% were de novo
mutations and 22% were inherited variants (12% recessively
inherited from both parents, 4% dominantly inherited from
an affected parent, 4% hemizygously inherited from mother to
son, and 2% inherited from a mosaic unaffected parent).
Thirty-three diagnoses are currently considered by the local
clinical team to be a partial explanation for the child’s
developmental disorder (i.e., the variant explains some but
not all of the child’s phenotypes), while at least six probands
have a dual diagnosis resulting in a compound or blended
phenotype (i.e., variants in two distinct genes/loci together
provide a full diagnosis for the child’s condition).11 An
additional 43 probands (4%) have variants of uncertain
clinical significance in known disease-associated genes, some
of which may become diagnostic in future as further evidence
accumulates.
The diagnostic yield increased by 13% as a result of
improvements made to the workflow (Table 1). Overall, 182
additional probands received a new diagnosis, 272 previously
diagnosed probands remained diagnosed, and 39 probands
had their previous diagnoses clinically reclassified as
uncertain or likely benign; a further 6 probands received a
diagnosis from an independent diagnostic test that was
missed by the DDD workflow due to low-depth sequencing
data in at least one member of the trio. Of the new diagnoses,
35% were in 30 new disease-associated genes discovered by
the DDD study itself,12,13,31 34% were in additional published
disease genes found through literature searches, 23% resulted
from improved analyses (such as updated annotations and
variant filtering thresholds), and 8% resulted from additional
analytical methods (Table 2).
A total of 838 variants were prioritized by our variant
analysis and filtering workflows in this cohort, an average of
~ 0.7 variants per proband (Figure 2). Following review by
two or more consultant clinical geneticists, 460 variants were
classified as likely or definitely pathogenic (either fully or
partially explaining the patient’s phenotype, Table 2), versus
328 in 2014; a further 378 were classified as uncertain, likely
benign, or benign for various reasons (lack of relevance of
gene to phenotype, MAF too high, alternative genetic
diagnosis in the proband, likely noncoding variant in the
relevant transcript, analytical false positive, unrelated parental
phenotype, or variant absent in affected sibling). The scale of
our data set allows us to estimate the diagnostic yield of
different classes of prioritized variants, which varies markedly
among different inheritance modes (Figure 3). Over 80% of
reported de novo mutations in dominant developmental
disease genes, but only 10% of inherited variants in the same
group of genes, were classed as likely or definitely pathogenic
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by our clinical teams. Of the 39 diagnoses that were reported
in 2014 and have since been retracted following clinical
assessment, 23 no longer meet our criteria for reporting.
The DDD study cohort excludes children who were
diagnosed using standard clinical genetic testing within the
NHS. Based on previous estimates of the diagnostic yield of
clinical microarrays of around 10%,32 plus a small additional
diagnostic yield from single-gene testing, we estimate that the
diagnostic yield of trio whole-exome sequencing would be
> 50% if implemented currently as a first-line test for
developmental disorders.
DISCUSSION
We have developed and implemented a scalable, automated,
and iterative method for reanalyzing, refiltering, re-reporting,
and re-evaluating candidate diagnostic variants for severe
developmental disorders from genome-wide sequence data,
which in principle should be readily applicable to a wide
Table 2 Summary of diagnoses and detection methods in the 454 diagnosed probands
Variant type Analysis method No. of diagnoses
Chromosomal aneuploidy Chromosome read-depth counter 2
Copy-number variants CNsolidate/CoNVex/CIPHER 50
De novo SNVs/indels in known genes DeNovoGear 232
De novo SNVs/indels in new DDD genes DeNovoGear/Discovery 58
De novo SNVs/indels in new external genes DeNovoGear/DDD Research Variant Track 5
De novo indels in known genes GATK candidate de novo variant 4
Inherited SNVs/indels in known genes GATK Mendelian filter 82
Inherited SNVs/indels in new DDD genes GATK Mendelian filter/Discovery 4
Large insertions/deletions Soft-clipped reads 4
Mosaic structural variants triPOD 5
Mosaic inherited SNVs/indels Parental mosaicism 4
Nonessential splice variants Splicing analysis 4
Uniparental disomy UPDio 6
Totala All 460
DDD, Deciphering Developmental Disorders study; GATK, Genome Analysis Toolkit; indel, insertion/deletion; SNV, single-nucleotide variant.
Reported variants that were considered by our clinical teams to explain all or part of a patient’s phenotype are summarized here; the variants themselves are available
with associated phenotypes through DECIPHER (https://decipher.sanger.ac.uk). All variants are in published developmental disorder genes with sufficient evidence to
merit inclusion on our clinician-curated gene-to-phenotype database (https://www.ebi.ac.uk/gene2phenotype/). Note that although most variants have been analytically
validated in an accredited diagnostic laboratory, functional studies have not been systematically performed to confirm clinical pathogenicity. Discovery indicates that a
new developmental gene was found and published by the DDD study.12,13,31
aIncludes six dual diagnoses.
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Figure 2 Summary of reported and diagnostic variants in 1,133 trios. The total number of candidate variants per proband using the 2017
analysis pipeline is indicated (black bars), along with the number of full or partially diagnostic variants per proband in 2017 (striped dark gray bars) and
2014 (light gray bars).
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range of rare diseases. There are numerous reasons why
reassessing genomic data is necessary, and will continue to
bear fruit into the future. Given the extraordinary period of
rapid development and discovery in genomics, both analytical
methods and variant databases become outdated very quickly.
For example, considerably more background population
variation data became available between our initial analysis
in 2014 and this analysis in 2017 (both internally from
unaffected parents within DDD, and externally from
resources such as ExAC),21 which is crucial to excluding
“normal” benign variation. Furthermore, around 200–300
additional disease-causing genes are published across all rare
diseases every year,7 which are vital for finding evidence-
based diagnoses within existing sequence data.
We have made a large number of evidence-based changes
and upgrades to our initial variant analysis and filtering
workflow within the DDD study (Table 1), including
improved and augmented variant calling and quality
control, updated variant annotation of predicted
consequence and allele frequency, improved variant filtering
thresholds, and additional disease-associated genes (286
additional genes were added to DDG2P between November
2013 and July 2016). Moreover, in addition to statistically
well-powered gene discovery within the DDD study itself,
made possible through pooling sequence data from families
with developmental disorders from across the United King-
dom, we have also catalyzed gene discovery by the wider
community by sharing plausibly pathogenic variants openly
through the DECIPHER database. These changes have yielded
substantial benefits. We are now able to diagnose an
additional 182 probands in our first 1,133 trios, taking our
total diagnostic yield from 27% in 2014 to 40% in 2017,
highlighting the value of ongoing curation, iterative reana-
lysis, and re-reporting. In addition, by using an expert
network of regional consultant clinical geneticists and
diagnostic laboratories, we have been able to revise a small
number of prior diagnoses through detailed clinical assess-
ment. Although a variety of genetic mechanisms and
inheritance patterns contribute to our diagnostic yield,
~ 80% of our diagnoses are de novo mutations that arose
spontaneously during reproduction and are not present in
either parent. Moreover, ~ 80% of reported de novo mutations
in a known-dominant developmental disorder were classed as
pathogenic by our clinical teams, emphasizing the utility of
trio sequencing as a first-line strategy in sporadic cases.
Many challenges remain for continuing to improve the
sensitivity and specificity of genomic sequencing. First,
achieving the right balance between identifying diagnostic
variants and over-reporting is problematic; the many detailed
decisions required are obscured by automated workflows and
hard-wired filtering thresholds. A rules-based approach will
always result in reporting some false positive variants and
missing some true positives. Clinical teams are usually quite
unaware of which parts of the genome they are not seeing, or
why, making unbiased evaluation of candidate variants
extremely difficult. Moreover, variant filtering is substantially
less effective for some patients and families. For family trios
where both parents are unaffected and there is no family
history, the majority of potentially diagnostic variants
reported from exome sequencing are novel de novo mutations
and are very likely to be causal; however, the converse is also
true, and where both parents share a similar phenotype, the
majority of reported variants are inherited and are unlikely to
be causal (Figure 3). The situation is even more challenging
0% 20% 40% 60% 80% 100%
Definitely pathogenicLikely pathogenicUncertainLikely benignBenign
De novo dominant
heterozygote (n = 414)
Dominantly inherited
heterozygote (n = 172)
Maternally inherited chrX
hemizygote (n = 72)
Recessively inherited
compound het (n = 109)
Recessively inherited
homozygote (n = 52)
Figure 3 Pathogenicity assessments of reported variants by inheritance class. All variants (including single-nucleotide variants, indels, copy-
number variants, structural variants, uniparental disomy, and aneuploidies) that were classified by clinical teams as definitely/likely pathogenic were
considered diagnostic, while those considered uncertain/likely benign/benign were not. The likelihood that a rare, functional de novo mutation in a
dominant DDG2P gene is considered pathogenic is > 80%, while the diagnostic yield from reported inherited variants is substantially less (10–30%).
Note that variants of unknown and mosaic inheritance are excluded from the diagram due to low numbers (no 10).
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for non-trios where the parents are unavailable for testing.14
Ever larger data sets of normal, benign variants will improve
this situation, as will improved tools for predicting the
pathogenicity of missense variants, but given that every family
has rare/private variants, individuals and families with rare
inherited dominant conditions may be better served by using
more tightly focused analyses that are specific to their
condition.
Second, diseases vary substantially in their genomic
footprint, and those that are highly genetically heterogeneous
will always be difficult to diagnose. The more genes that are
causally associated with similar or overlapping phenotypes,
the harder it is to be certain that any given variant is actually
the cause. Although our top diagnostic genes (ARID1B,
SATB2, SCN2A, ANKRD11, MED13L, and SYNGAP1)
together accounted for 55 diagnoses (5% of the cohort), the
substantial locus heterogeneity of developmental disorders
means that most genes only contribute a single diagnosis in
this cohort (Supplementary Figure S1 online), and we have
yet to find a diagnosis in the majority of the 1,400 genes on
our diagnostic gene list. Although more disease-associated
genes will be discovered, it is likely that these will be
increasingly rare in prevalence. Substantial allelic hetero-
geneity also makes variant interpretation challenging even in
known disease-causing genes.
Third, managing the expectations of clinicians and families
is extremely challenging in such a fast-moving field, as is
achieving clarity about the nature and scope of the obligations
of researchers and health professionals. Diagnoses can appear
at almost any time, even following a “negative report,” or can
be retracted as new evidence comes to light, or augmented by
additional variants that may—or may not—contribute to the
phenotype. Dual diagnoses resulting in blended phenotypes,
which may be overlapping or distinct, are particularly
challenging to untangle, as are “coincidental” findings in
phenotypically heterogeneous genes where variants can cause
both the disorder in question and another unrelated disorder.
Although determining whether a particular variant or
combination of variants explains the child’s phenotype—or
part of it, or none of it—is sometimes simple; other times it is
not and may require further clinical evaluation and
investigation. This uncertainty is the nature of a field where
research and clinical practice are so entwined. By requiring
peer-reviewed publication of disease-associated genes prior to
addition to our diagnostic gene list and diagnostic reporting
of causal variants, the DDD study has maintained a clear
demarcation between research analyses and clinical practice
to reduce some of this uncertainty. Through the DECIPHER
platform, we also provided clinical teams with the systems
and information necessary to help evaluate candidate variants.
However, decisions about when and how to contact (or
recontact) individual families with potential diagnoses are
ultimately for local clinical teams to judge, based on their
greater knowledge of the family.
Finally, a question remains as to how we should best
counsel the 673 families who still have no diagnoses after
several rounds of reanalyzing their data. How many more
diagnoses can we expect from this same cohort in another 3
years, or another 10, and what might be reasonable for a
family to expect in terms of follow-up? Large-scale sequencing
studies allow us to estimate what proportion of currently
undiagnosed patients are likely to be explained by a given
class of variation, such as dominant de novo mutations.13
However, in any cohort, there is likely to be a gray area
between definitively genetic conditions, where a single genetic
variant is the sole cause of disease, and those where multiple
variants and environmental factors play a role. We don’t yet
know what proportion of the DDD cohort have a monogenic
cause for their condition, and what fraction may have an
oligogenic or polygenic component. Nonetheless, in our initial
1,133 trios, we were unable to find any statistically significant
phenotypic differences between the diagnosed and undiag-
nosed groups (Supplementary Figures S2 and S3). Currently,
two-thirds of our novel diagnoses resulted from additional
new disease-associated genes over the last 3 years, and it is
therefore likely that the number of diagnoses will continue to
increase as more causal genes are discovered through
collaboration, data sharing, and meta-analyses. Although this
growth in disease-associated genes is likely to slow at some
point in the near future, at least for dominant diseases for
which trio whole-exome study designs are very powerful, it is
likely that very rare and recessive diseases will continue to be
discovered for many years to come. Some diagnoses will also
be missing from our data, due to low coverage in particular
coding regions, long repeats or structural variants not
detectable with short-read sequencing, or noncoding variants
not assayed by exome sequencing. Although this suggests that
whole-genome sequencing should increase our diagnostic
yield further, the additional yield from genome sequencing is
unlikely to be substantial given that we know of just six
“missed” diagnoses in our cohort. The emphasis for future
reanalysis and diagnostic reporting ought therefore to focus
on better curation of gene–disease relationships and the
continued coupling of research and clinical practice to enable
robust gene discovery.
This work has significant implications for diagnostic labora-
tory reports. We suggest that iterative reinterpretation of already
reported clinical sequencing data should become routine. This
would require a major cultural change in reporting that would
have implications for the development of appropriate infor-
matics systems, the prioritization of clinical expertise, and the
emotional burden on affected individuals and their families, all
of whom may have to deal with the uncertainty of diagnoses
emerging subsequently even following an initial negative report.
Further work is needed to investigate the logistical and
communication challenges, resource implications, and infor-
matics infrastructure required to implement systematic reinter-
pretation and recontact in clinical practice.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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